Results 271 to 280 of about 2,995,797 (334)

Knowledge structure and dynamic evolution of nanomedicine in liver cancer research: a scientometric analysis and visualization. [PDF]

Front Pharmacol
Li S, Cui D, Shao B, Kang Z, Yan G.
europepmc   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

FEBS Open Bio, EarlyView.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy, Arnaud Vigneron, Xavier Rousset, Jérome Guitton, Emmanuel Grolleau, Margaux Raffin, Julie Balandier, Gaëlle Lescuyer, Mathilde Bardou, Florence Geiguer, Sébastien Couraud, Claire Bardel, Jean Viallet, Nazim Benzerdjeb, Léa Payen   +14 more
wiley   +1 more source

Bibliometric and visual analysis of chronic stress in cancer research from 2014 to 2024. [PDF]

Discov Oncol
Wei Z, Li A, Su L, Zhang B, Yan Y.
europepmc   +1 more source

A potential tumor suppressor role of PLK2 in glioblastoma

FEBS Open Bio, EarlyView.
PLK2 was consistently downregulated in GBM tissues. Overexpression of PLK2 in GBM cell lines U87MG and U251 reduced their tumorigenic potential and enhanced cell cycle arrest and apoptosis. Suggesting that PLK2 overexpression could potentially be leveraged as a therapeutic strategy to inhibit tumor progression and enhance apoptosis, providing new ...
Xiangping Xia, Peirui Wang, Hua Xiao, Qishan Ran, Yan Li, Shengtao Yao   +5 more
wiley   +1 more source

Multidimensional analyses identify genes of high priority for pancreatic cancer research. [PDF]

JCI Insight
Nwosu ZC, Giza HM, Nassif M, Charlestin V, Menjivar RE, Kim D, Kemp SB, Sajjakulnukit P, Andren A, Zhang L, Lai WK, Loveless I, Steele N, Hu J, Hu B, Wang S, Pasca di Magliano M, Lyssiotis CA.   +17 more
europepmc   +1 more source

Identification of inhibitors of the Salmonella FraB deglycase, a drug target

FEBS Open Bio, EarlyView.
A high‐throughput screen was used to identify inhibitors of Salmonella FraB, a drug target. Characterization of top hits (identified after an additional counter screen) revealed that some triazolidines, thiadiazolidines, and triazolothiadiazoles are mixed‐type inhibitors of FraB.
Jamison D. Law, Yuan Gao, Sravya Kovvali, Pankajavalli Thirugnanasambantham, Vicki H. Wysocki, Brian M. M. Ahmer, Venkat Gopalan   +6 more
wiley   +1 more source

A two-decade bibliometric analysis of drug resistance in oral cancer research: patterns, trends, and future directions. [PDF]

Discov Oncol
Xu X, Wang Z.
europepmc   +1 more source

Beyond digital twins: the role of foundation models in enhancing the interpretability of multiomics modalities in precision medicine

FEBS Open Bio, EarlyView.
This review highlights how foundation models enhance predictive healthcare by integrating advanced digital twin modeling with multiomics and biomedical data. This approach supports disease management, risk assessment, and personalized medicine, with the goal of optimizing health outcomes through adaptive, interpretable digital simulations, accessible ...
Sakhaa Alsaedi, Xin Gao, Takashi Gojobori   +2 more
wiley   +1 more source

A student-community partnership to enhance cancer research training. [PDF]

BMC Med Educ
Melillo RJ, El Khoury C, Shaver AL, Cunningham M, Benavides N, Lacerda Q, Kim FJ, Leader AE.   +7 more
europepmc   +1 more source

Red blood cells could protect miRNAs from degradation or loss thanks to Argonaute 2 binding

FEBS Open Bio, EarlyView.
The present work investigates the presence and the stability of miRNAs into RBCs, both native and engineered. The observed stability is due to the Ago2 bound resulting in minimal RISC. Indeed, if the miRNA‐Ago2 complex is present, miRNAs are protected from release or degradation and they are biologically active. Thus, RBCs can act as miRNA carriers for
Elena Perla, Faiza Abbas, Luigia Rossi, Mauro Magnani, Sara Biagiotti   +4 more
wiley   +1 more source